PRVL - Prevail Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.90
+0.76 (+6.26%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close12.14
Open12.21
Bid0.00 x 3100
Ask0.00 x 2200
Day's Range11.77 - 13.25
52 Week Range7.41 - 16.90
Volume133,036
Avg. Volume147,404
Market Cap438.873M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-7.80
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.33
Trade prices are not sourced from all markets
  • GlobeNewswire

    Prevail Therapeutics Announces Addition to Russell 2000®, 3000® and Microcap® Indexes

    Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today announced that it will be added to the Russell 2000 and Russell 3000 and Microcap Indexes, effective after the close of the U.S. markets on Friday, September 20, 2019. The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity market. The index is a subset of the Russell 3000® Index and represents approximately 10 percent of the total market capitalization of that index.

  • GlobeNewswire

    Prevail Therapeutics Provides Program Update on PR001 in Parkinson’s Disease with GBA1 Mutations and Neuronopathic Gaucher Disease

    Prevail Therapeutics Inc. (NASDAQ: PRVL), a biotechnology company developing AAV-based gene therapies for patients with neurodegenerative disorders, today provided an update on the Company’s clinical development of PR001, a potentially disease-modifying, single-dose gene therapy in development for Parkinson’s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD). Prevail has an open Investigational New Drug Application (IND) for PR001 for the treatment of PD-GBA, the first indication the Company is pursuing.

  • GlobeNewswire

    Prevail Therapeutics to Present at Morgan Stanley 2019 Global Healthcare Conference

    NEW YORK, Sept. 04, 2019 -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based.

  • GlobeNewswire

    Prevail Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights

    IND Active for Phase 1/2 Trial of PR001 to Treat Parkinson’s Disease Patients with GBA1 Mutations Successful $125.0 Million Initial Public Offering Completed to Support.

  • GlobeNewswire

    Prevail Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference

    Prevail Therapeutics Inc. (Nasdaq: PRVL) (Prevail), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today announced that Asa Abeliovich, M.D., Ph.D., Founder and CEO, will present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019 at 10:20 a.m. ET in New York City. Prevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. Prevail was founded by Dr. Asa Abeliovich in 2017, through a collaborative effort with The Silverstein Foundation for Parkinson’s with GBA and OrbiMed, and is headquartered in New York, NY.

  • Benzinga

    Analysts Initiate Bullish Coverage Of Prevail Therapeutics

    Ahmad said Prevail’s leading asset PR001 has a potentially large indication for treating Parkinson’s via disease-modifying therapy. PR001 could also potentially be the first therapy ever approved for treatment of neuronopathic Gaucher disease. In addition, Ahmad said PR006 for frontotemporal dementia and PR004 for synucleinopathies are also potential sources of long-term value creation for Prevail investors.

  • Benzinga

    FDA Grants Fast Track Designation For Prevail's Parkinson's Treatment

    Prevail Therapeutics (NASDAQ: PRVL) shares are trading higher after the company received FDA fast track designation for PR001 for the treatment of Parkinson's disease patients with a GBA1 mutation. “We are pleased that the FDA has granted Fast Track Designation for PR001, which underscores the unmet need of patients with Parkinson’s disease with a GBA1 mutation, a chronic and progressive neurodegenerative disorder that comprises 7% to 10% of the total Parkinson’s disease population worldwide,” said CEO Asa Abeliovich.

  • GlobeNewswire

    Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Parkinson’s Disease Patients with a GBA1 Mutation

    Prevail Therapeutics Inc. (Nasdaq: PRVL) (Prevail), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the Company’s lead gene therapy program, PR001, for the treatment of Parkinson’s disease patients with a GBA1 mutation (PD-GBA). PR001 is a potentially disease-modifying, single-dose, AAV9-based gene therapy being developed for the treatment of PD-GBA and neuronopathic Gaucher disease.

  • Benzinga

    Prevail Therapeutics Opens Below IPO Price

    New York-based Prevail Therapeutics (NASDAQ: PRVL ) opened for trade Thursday afternoon at $15.31 per share. The 7.353-million share IPO was priced at $17. Prevail is a gene therapy company founded in ...

  • Business Wire

    Prevail Therapeutics Announces Pricing of Initial Public Offering

    Prevail Therapeutics Inc. , a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today announced the pricing of its initial public offering of 7,353,000 shares of its common stock at a price to the public of $17.00 per share.

  • Benzinga

    Prevail Therapeutics IPO: What You Need To Know

    Want to partake in the gene therapy revolution that is emerging as a new paradigm in drug development? New York-based Prevail Therapeutics is planning a 7.353-million share IPO, estimated to be priced between $16 and $18, according to the S-1/A filing from June 10. The company has applied for listing its shares on the Nasdaq under the ticker symbol PRVL.

  • Benzinga

    IPO Outlook For The Week: Biotechs And A Grocery Outlet

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Stoke Therapeutics, Inc. (STOK) will issue 6.7 million shares between ...